Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Latest, FY2025
1,366
Period ended Dec 31, 2025
Change on a year earlier
-15.5%
1,616 in FY2024
History
12 years
Since FY2012
Sources
10
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Deferred tax liabilities ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,366 | -15.5% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 1,616 | -31.4% | Form 10-K (filed 2025-02-14) ↗ |
| FY2023 | Dec 31, 2023 | 2,354 | +21,300.0% | Form 10-K (filed 2024-02-14) ↗ |
| FY2022 | Dec 31, 2022 | 11 | – | Form 10-K (filed 2024-02-14) ↗ |
| FY2019 | Dec 31, 2019 | 606 | -29.9% | Form 10-K (filed 2020-02-12) ↗ |
| FY2018 | Dec 31, 2018 | 864 | -25.9% | Form 10-K (filed 2019-02-13) ↗ |
| FY2017 | Dec 31, 2017 | 1,166 | -52.1% | Form 10-K (filed 2018-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 2,436 | +8.8% | Form 10-K (filed 2017-02-14) ↗ |
| FY2015 | Dec 31, 2015 | 2,239 | -35.3% | Form 10-K (filed 2016-02-16) ↗ |
| FY2014 | Dec 31, 2014 | 3,461 | -1.1% | Form 10-K (filed 2015-02-19) ↗ |
| FY2013 | Dec 31, 2013 | 3,498 | +288.7% | Form 10-K (filed 2015-02-19) ↗ |
| FY2012 | Dec 31, 2012 | 900 | – | Form 10-K (filed 2014-02-24) ↗ |
Cite this data
StockData. (2026). Amgen Deferred tax liabilities ($M) ($M), annual FY2012–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/fs_dtl
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.